With the oft-cited patent cliff looming, big pharma companies are still looking to replenish pipelines. For many, partnering represents an important avenue to do so with its more limited financial risk, compared to a full acquisition. According to Biomedtracker, the total value of partnership deals in 2023 was $185.62bn, and there is a broad sentiment that the volume of deals will increase this year. With biotechs increasingly short on cash, at risk of restructuring and looking for investment, penning such a partnership presents an opportunity to sustain operations.
What Big Pharmas Are Looking For In Partners
With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.
